Replimune Group (NASDAQ:REPL) Receives “Buy” Rating from HC Wainwright

Replimune Group (NASDAQ:REPL)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $17.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 53.85% from the stock’s current price.

Several other equities research analysts have also commented on the stock. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, JPMorgan Chase & Co. boosted their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $16.80.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $11.05 on Friday. The stock has a market capitalization of $756.04 million, a price-to-earnings ratio of -3.62 and a beta of 1.19. Replimune Group has a one year low of $4.92 and a one year high of $12.97. The company has a 50-day simple moving average of $11.50 and a 200-day simple moving average of $9.66. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, analysts predict that Replimune Group will post -3.02 EPS for the current year.

Insider Activity

In related news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently made changes to their positions in REPL. Quest Partners LLC boosted its stake in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the last quarter. Algert Global LLC raised its holdings in shares of Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after purchasing an additional 4,340 shares during the period. Creative Planning lifted its stake in shares of Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after purchasing an additional 4,699 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the period. Finally, Los Angeles Capital Management LLC increased its position in Replimune Group by 8.1% during the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after purchasing an additional 5,410 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.